Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
Public ClinicalTrials.gov record NCT00737100. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 mcg and 5 mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations
Study identification
- NCT ID
- NCT00737100
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 510 participants
Conditions and interventions
Conditions
Interventions
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2008 (Type not available)
- Primary completion
- Apr 2010 (Actual)
- Completion
- Not listed
- Last update posted
- May 16, 2014
Started 2008
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 205.339.006 Boehringer Ingelheim Investigational Site | Tucson | Arizona | — | — |
| 205.339.019 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 205.339.023 Boehringer Ingelheim Investigational Site | Jacksonville | Florida | — | — |
| 205.339.021 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 205.339.030 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 205.339.031 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 205.339.014 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 205.339.022 Boehringer Ingelheim Investigational Site | Indianapolis | Indiana | — | — |
| 205.339.013 Boehringer Ingelheim Investigational Site | South Bend | Indiana | — | — |
| 205.339.001 Boehringer Ingelheim Investigational Site | Iowa City | Iowa | — | — |
| 205.339.017 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 205.339.025 Boehringer Ingelheim Investigational Site | Detroit | Michigan | — | — |
| 205.339.016 Boehringer Ingelheim Investigational Site | Grand Rapids | Michigan | — | — |
| 205.339.018 Boehringer Ingelheim Investigational Site | Lebanon | New Hampshire | — | — |
| 205.339.029 Boehringer Ingelheim Investigational Site | Long Branch | New Jersey | — | — |
| 205.339.009 Boehringer Ingelheim Investigational Site | Morristown | New Jersey | — | — |
| 205.339.002 Boehringer Ingelheim Investigational Site | Syracuse | New York | — | — |
| 205.339.024 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 205.339.020 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.339.032 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | — | — |
| 205.339.010 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 205.339.004 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 205.339.005 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | — | — |
| 205.339.026 Boehringer Ingelheim Investigational Site | Colchester | Vermont | — | — |
| 205.339.011 Boehringer Ingelheim Investigational Site | Charlottesville | Virginia | — | — |
| 205.339.003 Boehringer Ingelheim Investigational Site | Milwaukee | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 81 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00737100, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 16, 2014 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00737100 live on ClinicalTrials.gov.